Erratum to: STrengthening the reporting of OBservational studies in Epidemiology—Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement

[1]  S. Pocock,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, PLoS medicine.

[2]  J. Ioannidis,et al.  The False-positive to False-negative Ratio in Epidemiologic Studies , 2011, Epidemiology.

[3]  J. Ioannidis,et al.  Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. , 2011, JAMA.

[4]  John P A Ioannidis,et al.  New Prognostic Markers for Outcome of Acute Pancreatitis: Overview of Reporting in 184 Studies , 2011, Pancreas.

[5]  D. Altman,et al.  the Creative Commons Attribution Non-Commercial , 2011 .

[6]  John P. A. Ioannidis,et al.  An empirical assessment of validation practices for molecular classifiers , 2011, Briefings Bioinform..

[7]  G. Antes,et al.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials , 2011 .

[8]  L. Casteleyn,et al.  Ethics and data protection in human biomarker studies. , 2010 .

[9]  M. Kirsch‐Volders,et al.  Phenotyping for DNA repair capacity. , 2010, Mutation research.

[10]  David M. Simcha,et al.  Tackling the widespread and critical impact of batch effects in high-throughput data , 2010, Nature Reviews Genetics.

[11]  Tye E Arbuckle,et al.  Reporting results of human biomonitoring of environmental chemicals to study participants: a comparison of approaches followed in two Canadian studies , 2010, Journal of Epidemiology & Community Health.

[12]  John P A Ioannidis,et al.  What makes a good predictor?: the evidence applied to coronary artery calcium score. , 2010, JAMA.

[13]  D. Moher,et al.  CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials , 2010, Journal of pharmacology & pharmacotherapeutics.

[14]  D. Moher,et al.  Guidance for Developers of Health Research Reporting Guidelines , 2010, PLoS medicine.

[15]  D. Moher,et al.  A catalogue of reporting guidelines for health research , 2010, European journal of clinical investigation.

[16]  D. Bild,et al.  Score What Makes a Good Predictor ? : The Evidence Applied to Coronary Artery Calcium , 2010 .

[17]  Paolo Vineis,et al.  Epidemiology, Public Health, and the Rhetoric of False Positives , 2009, Environmental health perspectives.

[18]  M. Porta,et al.  Influence of tumor stage, symptoms, and time of blood draw on serum concentrations of organochlorine compounds in exocrine pancreatic cancer , 2009, Cancer Causes & Control.

[19]  J. Ioannidis,et al.  Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. , 2009, Journal of clinical epidemiology.

[20]  E. Faerstein,et al.  A DICTIONARY OF EPIDEMIOLOGY , 2016 .

[21]  D G Altman,et al.  Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond , 2009, British Journal of Cancer.

[22]  John P A Ioannidis,et al.  Overinterpretation of clinical applicability in molecular diagnostic research. , 2009, Clinical chemistry.

[23]  S. Bakri,et al.  Applying the CONSORT and STROBE statements to evaluate the reporting quality of neovascular age-related macular degeneration studies. , 2009, Ophthalmology.

[24]  Paolo Vineis,et al.  Molecular Epidemiology of Chronic Diseases , 2008 .

[25]  D. Moher,et al.  Guidelines for Reporting Health Research: The EQUATOR Network's Survey of Guideline Authors , 2008, PLoS medicine.

[26]  P. Vineis,et al.  Validation of biomarkers for the study of environmental carcinogens: a review , 2008, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[27]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[28]  John P A Ioannidis,et al.  Almost all articles on cancer prognostic markers report statistically significant results. , 2007, European journal of cancer.

[29]  S. Pocock,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. , 2007, Annals of internal medicine.

[30]  Paolo Vineis,et al.  Molecular Epidemiology and Biomarkers in Etiologic Cancer Research: The New in Light of the Old , 2007, Cancer Epidemiology Biomarkers & Prevention.

[31]  J. Ioannidis.  Genetic and molecular epidemiology , 2007, Journal of Epidemiology and Community Health.

[32]  P. Vineis,et al.  Epidemiological concepts of validation of biomarkers for the identification/quantification of environmental carcinogenic exposures. , 2007 .

[33]  N. Malats,et al.  Timing of blood extraction in epidemiologic and proteomic studies: results and proposals from the PANKRAS II Study , 2007, European Journal of Epidemiology.

[34]  M. Porta.  A dictionary of epidemiology, 5th edition. A call for submissions through an innovative wiki , 2006 .

[35]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[36]  A. Harris,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.

[37]  Paolo Vineis,et al.  Design Options for Molecular Epidemiology Research within Cohort Studies , 2005, Cancer Epidemiology Biomarkers & Prevention.

[38]  John P A Ioannidis,et al.  Selective reporting biases in cancer prognostic factor studies. , 2005, Journal of the National Cancer Institute.

[39]  Paolo Vineis,et al.  Individual susceptibility to carcinogens , 2004, Oncogene.

[40]  D. Ransohoff.  Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.

[41]  Harri Vainio,et al.  Genetic biomarkers and occupational epidemiology--recollections, reflections and reconsiderations. , 2004, Scandinavian journal of work, environment & health.

[42]  K. Vähäkangas.  Ethical aspects of molecular epidemiology of cancer. , 2003, Carcinogenesis.

[43]  P. Bossuyt,et al.  BMC Medical Research Methodology , 2002 .

[44]  Steffen Loft,et al.  Personal exposure to PM2.5 and biomarkers of DNA damage. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[45]  KAI HIRSCHMANN,et al.  The Changing Face of , 2003 .

[46]  N. Caporaso.  Why have we failed to find the low penetrance genetic constituents of common cancers? , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[47]  Piero Dolara,et al.  Nutritional and lifestyle determinants of DNA oxidative damage: a study in a Mediterranean population. , 2002, Carcinogenesis.

[48]  M. Dusinska,et al.  DNA damage and antioxidants; fluctuations through the year in a central European population group. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[49]  R. Millikan.  The Changing Face of Epidemiology in the Genomics Era , 2002, Epidemiology.

[50]  Herman Autrup,et al.  Exposure to genotoxins present in ambient air in Bangkok, Thailand--particle associated polycyclic aromatic hydrocarbons and biomarkers. , 2002, The Science of the total environment.

[51]  Stefano Bonassi,et al.  Biomarkers in molecular epidemiology studies for health risk prediction. , 2002, Mutation research.

[52]  Erik Holst,et al.  Sunlight‐induced DNA damage in human mononuclear cells , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[53]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[54]  P. Boffetta.  Molecular epidemiology , 2001, Journal of internal medicine.

[55]  D G Altman,et al.  What do we mean by validating a prognostic model? , 2000, Statistics in medicine.

[56]  D. Hunter,et al.  The future of molecular epidemiology. , 1999, International journal of epidemiology.

[57]  D. Phillips,et al.  Standardization and validation of DNA adduct postlabelling methods: report of interlaboratory trials and production of recommended protocols. , 1999, Mutagenesis.

[58]  P. Vineis,et al.  Sources of variation in biomarkers. , 1997, IARC scientific publications.

[59]  N. Black.  CONSORT , 1996, The Lancet.

[60]  P. Kristensen.  Bias from Nondifferential but Dependent Misclassification of Exposure and Outcome , 1992, Epidemiology.

[61]  C. Arias,et al.  1543. Validation of a Nitrocefin-based Rapid Test for the Detection of the Cefazolin Inoculum Effect in Pediatric Patients with Methicillin-Susceptible Staphylococcus aureus Acute Osteomyelitis , 2022, Open Forum Infectious Diseases.